This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Valeant Buys Sanitas to Broaden Generics

MISSISSAUGA, Ontario ( TheStreet) -- Canada's Valeant Pharmaceuticals (VRX - Get Report) agreed to acquire Lithuania-based AB Sanitas for about €314 million ($442.1 million) in cash, and assume about €50 million of debt.

Sanitas is a pharmaceuticals company with a generics portfolio of 390 products in nine countries throughout Central and Eastern Europe, primarily Poland, Russia and Lithuania.

Valeant said the transaction is expected to be immediately accretive to its earnings.

"The acquisition of Sanitas should provide Valeant with an exciting opportunity to expand our European branded generics product portfolio with dermatology and hospital injectable compounds that have a strong track record of growth and profitability," said J. Michael Pearson, Valeant's chairman and CEO, in a statement Tuesday. "With 80% of the Sanitas portfolio consisting of non-reimbursed products with limited exposure to government pricing pressures, Valeant will be in a key position to continue our expansion into Central and Eastern Europe."

Valeant's move to acquire Sanitas comes on the heels of its losing out on its $5.7 billion bid to buy Cephalon (CEPH). Israel's Teva Pharmaceutical (TEVA - Get Report) topped Valeant's bid for Cephalon.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to:

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
TEVA $62.32 0.24%
VRX $224.50 0.66%
AAPL $129.93 0.76%
FB $78.98 -0.01%
GOOG $539.42 0.28%


DOW 18,111.77 +87.71 0.49%
S&P 500 2,119.02 +10.73 0.51%
NASDAQ 5,038.2820 +32.8910 0.66%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs